Faculty : Departmental- Primary

Barry I. Hudson, Ph.D.

Dr. Hudson’s research focusses on how inflammation increases breast cancer metastasis, and how inflammatory comorbidities including obesity and diabetes drives breast cancer progression and metastasis. Specifically, Dr. Hudson’s work focuses on the Receptor for Advanced Glycation End-products (RAGE) and its ligands that participate in many malignant states including breast cancer.

Dr. Hudson’s group have found RAGE promotes breast cancer progression and metastasis and have developed novel therapeutic approaches to target RAGE. Current efforts in the lab are focused on elucidating mechanisms how inflammation drives metastasis and performing preclinical studies with RAGE inhibitors in order to translate these findings to clinical trials in women with aggressive and metastatic cancer.


Click here for information on: DOD Funds Study of Link between Diabetes and Breast Cancer

Biographical Information

BSc University of Leeds, 1996

PhD University of Leeds, 2001

Postdoctoral: Department of Surgery, Columbia University (2002-2005)

Associate Research Scientist: Department of Surgery, Columbia University (2005-2010)

Research Assistant Professor: Division of Endocrinology (2010)

Assistant Professor, Department of Cell Biology

Professional Affiliations

University of Miami Sylvester Comprehensive Cancer Center

Select Publications

  • Hudson BI and Lippman ME. (2018) Targeting RAGE signaling in inflammatory disease. Ann Rev Med (Review).
  • Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI. (2017) Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 36, 1559-1572
  • Miller, P., Kidwell, K. M., Thomas, D. B., Sabel, M., Rae, J. M., Hayes, D. F., Hudson, B., El-Ashry, D., Lippman, M. E. (2017). Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome. Breast cancer research and treatment, 166(1), 85-94
  • Braley A, Kwak T, Jules J, Harja E, Landgraf R,* Hudson BI*. (2016) Regulation of RAGE ectodomain shedding and its role in cell function J Biol Chem 291(23):12057-73.
  • Jules J, Miaguel D, Hudson BI. (2013) Alternative splicing of the RAGEcytoplasmic domain regulates cell signaling and function. PLOS ONE8;8(11):e78267.
  • Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, Paik MC, Yoshita M, Sacco RL, DeCarli C, Wright CB, Elkind MS (2011) Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis. 216(1):192-8.
  • Kalea AZ, See F, Harja E, Arriero M, Schmidt AM, Hudson BI. (2010). Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling. Cancer Res. 70(13):5628-38.